Tempus AI Advances Hereditary Cancer Testing and Immunotherapy Prediction, Despite Share Price Decline

Tempus AI has contributed to research using advanced genetic assays to refine hereditary cancer variant interpretation, reaching a milestone of 1,000,000 combined DNA and RNA tests completed. The company also validated its Immune Profile Score test, outperforming current standards in predicting immunotherapy outcomes. Despite a 17.1% decline over the past week and a 22.6% decline over the past year, the company continues to push new tools and assays into clinical research and practice.